[Primary angioplasty is elective reperfusion therapy in the treatment of acute myocardial infarction. Arguments against].
The primary goal of treatment for patients with evolving infarction should be the rapid and sustained restoration of antegrade coronary blood flow. Thrombolytic therapy is an effective and widely available therapy to achieve this aim. However, thrombolysis does not achieve recanalization of the infarct-related artery in 20% of patients and early complete reperfusion (TIMI 3 flow) is achieved in only 50%. Some small randomized trials suggested that primary angioplasty was more effective than thrombolytic therapy in restoring patency and preventing reocclusion of the infarct-related artery. Furthermore, the patients treated with immediate angioplasty had a lower incidence of recurrent ischemia, reinfarction and death than those given thrombolysis. More recently, the GUSTO IIb primary angioplasty substudy, found that primary angioplasty provided only a small short-term clinical benefit over thrombolytic therapy with t-PA, in the combined end-point of death, reinfarction and nonfatal disabling stroke at 30 days. At six months, this small benefit had vanished. The major limitation for primary angioplasty is the restricted availability of the procedure. Only when angioplasty can be performed promptly, in centers with extensive experience in angioplasty and with adequate catheterization facilities and support personnel, may it be used as the reperfusion strategy of choice. Nowadays, for the vast majority of patients, thrombolysis remains the best available treatment for acute myocardial infarction.